SEATTLE, March 17, 2025 /PRNewswire/ -- Mozart Therapeutics, the leading developer of CD8 Treg modulators for the treatment of autoimmune disease, today announce the successful completion of their ...
Mozart Therapeutics Inc. has reported preclinical pharmacologic and tolerability data for MTX-101, a bispecific CD8 regulatory T-cell (Treg) modulator targeting inhibitory KIR2DL(1/2/3) and CD8 ...
Data show clear evidence of anti-tumor activity and durable partial and complete responses in heavily pre-treated patients with tumors that progressed through checkpoint inhibitors AU-007’s unique ...
Presentations underscore Mozart's commitment to advancing scientific understanding of the CD8 Treg network and developing therapies that restore endogenous CD8 Treg mechanisms for the treatment of ...
In autoimmune diseases such as inflammatory bowel disease (IBD), the function of regulatory CD8 T cells (CD8 Treg) is compromised, in part due to the expression of inhibitory KIR receptors ...
TangGene names former GSK SVP Catherine Sohn as Senior Strategic Advisor, strengthening leadership as it advances a first-in-class in-vivo CD8⁺ Treg therapy. TangGene’s in-vivo CD8⁺ Treg approach has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results